# Dosing & Timing

### We Are At The Starting Line <a href="#the-honest-starting-point" id="the-honest-starting-point"></a>

There is no established therapeutic dose of shikonin for any cancer indication in humans. No dose-finding trial, no phase 1 pharmacokinetic study, no dose-escalation protocol has been completed and reported for shikonin as an anticancer agent.

***

### The One Human Clinical Signal That Exists <a href="#the-one-human-clinical-signal-that-exists" id="the-one-human-clinical-signal-that-exists"></a>

One finding in the literature comes closest to human clinical dosing data in an oncology context — and it needs to be reported accurately, not inflated.

A study cited in the resistance literature noted that a **shikonin mixture was used in 19 patients with later-stage lung cancer** who were not suitable for surgery or conventional treatment. After 18 months of treatment, cells developed only a 2-fold resistance to shikonin — a remarkably low resistance profile compared to conventional chemotherapy agents, which typically generate much higher resistance over the same period. No cross-resistance to cisplatin, paclitaxel, or shikonin analogues was observed.

This is the most cited near-clinical finding in the shikonin oncology literature.

What it tells us:

* A shikonin-containing preparation was administered to human cancer patients
* The resistance profile over 18 months was unusually low
* This is consistent with shikonin's multi-mechanism cell-death profile — it is mechanistically harder for cancer cells to fully escape than single-pathway agents

What it does not tell us:

* The formulation used is not specified as isolated shikonin — it was a mixture
* No dose in milligrams per kilogram or per day is reported in available summaries
* No pharmacokinetic data (plasma levels, tissue concentrations) was captured
* The study predates current reporting standards and has not been replicated in a controlled trial
* 19 patients is not a trial cohort — it is a case series at best

The 2025 Frontiers in Pharmacology review mentions that "according to preliminary clinical trials, shikonin may improve the effectiveness of known chemotherapeutic drugs, radiation therapies, and immunotherapies through synergistic and additive interactions." This language suggests the authors are aware of small early human observations — but no specific trial data is cited in retrievable form.

The honest characterisation: **one small, early, incompletely reported human observation exists.** It is interesting. It is not a dosing guide.

***

### What Laboratory and Animal Studies Used <a href="#what-laboratory-and-animal-studies-used" id="what-laboratory-and-animal-studies-used"></a>

This is what the research literature is actually built on.

**Cell-line concentrations:**\
Most in vitro studies use shikonin at concentrations of **0.5 μM to 20 μM**, with the majority of mechanistic work clustered between 2 and 10 μM. These concentrations are dissolved in DMSO or ethanol carrier in cell culture media — not achieved through oral administration.

**Animal study doses:**\
In xenograft and tumour models, doses typically range from **2 to 10 mg/kg** administered intraperitoneally or intravenously. In the PKM2/melanoma and lung carcinoma mouse study, shikonin was given at 5 mg/kg intraperitoneally and produced significant tumour volume reduction compared to control.

In the acute toxicity data, no behavioural changes or mortality were observed in mice at oral doses up to 20 mg/kg.

**The translation problem:**\
Converting an intraperitoneal mouse dose to a meaningful human oral dose is not a straightforward calculation. It requires human bioavailability data — which does not exist for shikonin in oncology settings. A standard allometric scaling from mouse to human (using a 12:1 body surface area conversion factor) would place 5 mg/kg in a mouse at roughly 0.4 mg/kg in a human — approximately 28 mg for a 70 kg person. But that calculation assumes equivalent oral bioavailability, which is precisely the variable that is unresolved.

***

### What the New Liposomal Formulation Offers — and Doesn't <a href="#what-the-new-liposomal-formulation-offers--and-doe" id="what-the-new-liposomal-formulation-offers--and-doe"></a>

The commercially available liposomal shikonin preparation (30 mg per capsule) is the first consumer-grade formulation designed to address the bioavailability gap.

It does not come with clinical pharmacokinetic data. No published study has measured plasma concentrations or tissue distribution in humans following oral liposomal shikonin dosing. The formulation is an important development — it makes the delivery science plausible in a way that raw extract preparations do not. It does not tell us what concentration arrives at tumour tissue, whether that concentration is sufficient for the mechanisms documented in laboratory work, or how frequently dosing needs to occur.

The manufacturer's dosing recommendation exists as a commercial starting point, not a clinical protocol.

***

### Timing — What the Mechanism Suggests, Not What Has Been Tested <a href="#timing--what-the-mechanism-suggests-not-what-has-b" id="timing--what-the-mechanism-suggests-not-what-has-b"></a>

No human data exists on timing relative to other treatments, meals, or time of day.

What the mechanism can inform:

**Relative to endocrine therapy:** Shikonin's CYP3A4 and CYP2D6 inhibition means timing relative to aromatase inhibitors or tamoxifen matters pharmacokinetically.&#x20;

**Relative to chemotherapy:** Preclinical synergy studies did not establish timing sequences. Whether shikonin should be given before, during, or after a chemotherapy infusion to maximise synergy or minimise toxicity is unknown.

***

### Resistance Profile — the Most Encouraging Dosing-Adjacent Finding <a href="#resistance-profile--the-most-encouraging-dosing-a-d" id="resistance-profile--the-most-encouraging-dosing-a-d"></a>

One finding from the human-adjacent data deserves emphasis in the dosing context.

After 18 months of treatment in the lung cancer observation, resistance to shikonin was only 2-fold — compared to the much higher resistance typically seen with conventional agents over the same period. Gene expression analysis showed cancer cells responded strongly to shikonin but failed to effectively mobilise drug resistance machinery.

This low resistance profile is mechanistically coherent. **A compound that kills via apoptosis, necroptosis, and ferroptosis simultaneously** — while targeting PKM2 and ERα through independent pathways — presents cancer cells with a multi-front challenge that is harder to escape than single-target therapy. The implication for long-term dosing is that resistance accumulation may be slower than with conventional agents — but this is a hypothesis drawn from one small observation, not a proven clinical property.

***

### Bottom Line <a href="#bottom-line" id="bottom-line"></a>

The literature can tell you what researchers used. It cannot tell you what dose to take, how often, at what time, or how to space it relative to treatment. The 19-patient lung cancer observation is the only near-human oncology dosing data that exists, and it reports outcomes without providing a dose. Until properly designed phase 1 and phase 2 trials are conducted — with plasma pharmacokinetics, dose escalation, and safety monitoring alongside standard treatment — this page cannot be more specific than it is.

That is not a failure of this page. It is an accurate reflection of where the field currently stands.

***

*This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.*

***

### References <a href="#references" id="references"></a>

Anticancer agent shikonin is an incompetent inducer of drug resistance — 19-patient lung cancer clinical observation and 18-month resistance data. *PLoS ONE* (2013).\
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052706>

Ahmad F et al. (2024). Shikonin in breast cancer treatment — concentration ranges used in research.\
<https://academic.oup.com/jpp/article/76/8/967/7656703>

Shikonin inhibits tumour growth in mice by suppressing PKM2-mediated aerobic glycolysis — animal dosing data (5 mg/kg IP). *Scientific Reports* (2018).\
<https://www.nature.com/articles/s41598-018-31615-y>

Shikonin enhances hypnotic effect and synergistic properties of diazepam — acute oral toxicity data in mice. *Journal of Ethnopharmacology* (2025).\
<https://www.sciencedirect.com/article/abs/pii/S1876382025000605>

Frontiers in Pharmacology (2025). Preliminary clinical trial reference — shikonin and conventional therapy synergy in female carcinomas.\
<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627124/full>

Liu Y et al. (2017). CYP450 inhibition by shikonin — timing implications for drug co-administration.\
<https://pubmed.ncbi.nlm.nih.gov/28941798/>

Shikonin Pro Liposomal — 30 mg capsule formulation reference. *MCS Formulas* (2025).\
<https://www.mcsformulas.com/vitamins-supplements/shikonin-liposomal/>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/dosing-and-timing.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.